Abstract
In a small trial involving children with progressive high-grade gliomas, direct infusions of a genetically engineered strain of herpes simplex virus elicited responses in 11 of 12 recipients. The therapy also led to more than a doubling in average patient survival compared with historical expectations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
